Article
Medicine, General & Internal
Thomas Jouve, Melanie Daligault, Johan Noble, Florian Terrec, Farida Imerzoukene, Celine Dard, Beatrice Bardy, Paolo Malvezzi, Lionel Rostaing
Summary: This study investigated the effect of adding Tocilizumab to a standard desensitization regimen. The results showed that Tocilizumab helped control post-transplant antibody rebound, especially for patients with higher baseline levels. However, there was no significant difference in pre-transplant antibody reduction with or without Tocilizumab. Further research is needed to validate these preliminary findings.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
Tania Colasanti, Francesca Romana Spinelli, Cristiana Barbati, Fulvia Ceccarelli, Susanna Scarpa, Marta Vomero, Cristiano Alessandri, Guido Valesini, Fabrizio Conti
Summary: This study investigates the impact of Belimumab (BLM) on autophagy and citrullination, finding that BLM treatment can decrease autophagy and citrullination levels in patients with SLE, as well as affect IL-18 concentration.
Article
Cardiac & Cardiovascular Systems
Hericka Bruna Figueiredo Galvao, Quynh Nhu Dinh, Jordyn M. Thomas, Flavia Wassef, Henry Diep, Alex Bobik, Christopher G. Sobey, Grant R. Drummond, Antony Vinh
Summary: The effect of reducing antibody-secreting cells (ASCs) on angiotensin II-induced hypertension was tested using the proteasome inhibitor bortezomib. ASCs and antibody levels were decreased, but hypertension was not affected.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Hematology
Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Sosana Delimpasi, Emmanouil Spanoudakis, Vasiliki Labropoulou, Ioannis Ntanasis-Stathopoulos, Annita-Ioanna Gkioka, Nikos Giannakoulas, Nikolaos Kanellias, Theodosia Papadopoulou, Aggeliki Sevastoudi, Eyrydiki Michalis, Maria Papathanasiou, Maria Kotsopoulou, Anastasia Sioni, Theodora Triantafyllou, Aikaterini Daiou, Mavra Papadatou, Marie-Christine Kyrtsonis, Anastasia Pouli, Ioannis Kostopoulos, Evgenia Verrou, Meletios-Athanasios Dimopoulos, Evangelos Terpos
Summary: We evaluated the efficacy and prognostic impact of VRd or DBQ compared to BSC or CT in pPCL patients. Among the studied patients, 37% had cPCS 5%-19%. Treatment with VRd/DBQ strongly correlated with a higher complete response rate (41% vs. 17%).
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Surgery
Edward T. Horn, Qingyong Xu, Julie N. Dibridge, Jessica H. Huston, Gavin W. Hickey, David J. Kaczorowski, Mary E. Keebler, Adriana Zeevi
Summary: This study investigated the use of proteasome inhibitor (PI) in the treatment of antibody-mediated rejection (AMR) in heart transplantation. The results showed that PI treatment significantly reduced strong donor-specific antibodies (DSA) and improved graft dysfunction in AMR patients. Larger studies are needed to further evaluate the effectiveness of PI in treating AMR.
CLINICAL TRANSPLANTATION
(2023)
Review
Urology & Nephrology
Yohan Park, Eun Jeong Ko, Byung Ha Chung, Chul Woo Yang
Summary: In kidney transplantation, patients with preexisting donor-specific antibodies against HLA face challenges in finding suitable donors. Accurate evaluation of sensitization level using methods like Luminex is crucial. Advances in DSA removal methods have improved success rates of HLAi KT.
KIDNEY RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Multidisciplinary Sciences
Mengmeng Dong, Jinna Zhang, Xiaoyan Han, Jingsong He, Gaofeng Zheng, Zhen Cai
Summary: This study retrospectively analyzed clinical data of 155 MM patients and found that baseline PN was age-related, leading to more severe BiPN during bortezomib induction therapy and worse PN outcome after induction therapy. MM patients with baseline PN also had worse PFS and OS.
SCIENTIFIC REPORTS
(2022)
Article
Biology
Monica Benvenuto, Valentina Angiolini, Chiara Focaccetti, Daniela Nardozi, Camilla Palumbo, Raffaele Carrano, Alessandra Rufini, Riccardo Bei, Martino Tony Miele, Patrizia Mancini, Giovanni Barillari, Mara Cirone, Elisabetta Ferretti, Grazia Raffaella Tundo, Luciano Mutti, Laura Masuelli, Roberto Bei
Summary: In this study, it was found that Bortezomib (Bor) can inhibit cell proliferation and induce apoptosis in malignant mesothelioma (MM) cells. Bor reduces the sensitivity of cells to the drug's cytotoxic effects by activating the Unfolded Protein Response. In in vivo experiments in mice, Bor can suppress MM growth, extend survival, and increase activation of T lymphocytes in the tumor microenvironment.
Article
Chemistry, Medicinal
Markus Klein, Michael Busch, Manja Friese-Hamim, Stefano Crosignani, Thomas Fuchss, Djordje Musil, Felix Rohdich, Michael P. Sanderson, Jeyaprakashnarayanan Seenisamy, Gina Walter-Bausch, Ugo Zanelli, Philip Hewitt, Christina Esdar, Oliver Schadt
Summary: Proteasomes are essential components of the ubiquitin-dependent protein degradation pathway, with LMP7 being a subunit of the immunoproteasome. Current pan-proteasome inhibitors nonselectively target LMP7 and other subunits, limiting their therapeutic applicability. Novel amido boronic acids were discovered to selectively inhibit LMP7, leading to the identification of the highly potent and orally available inhibitor M3258, which showed strong antitumor activity in MM models.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Davine Hofste Op Bruinink, Rowan Kuiper, Mark van Duin, Tom Cupedo, Vincent H. J. van der Velden, Remco Hoogenboezem, Bronno van der Holt, H. Berna Beverloo, Erik T. Valent, Michael Vermeulen, Francesca Gay, Annemiek Broijl, Herve Avet-Loiseau, Nikhil C. Munshi, Pellegrino Musto, Philippe Moreau, Sonja Zweegman, Niels W. C. J. van de Donk, Pieter Sonneveld
Summary: This study successfully identified pPCL and classified 10% of NDMM tumors as PCL-like by constructing a transcriptomic classifier, indicating the presence of a specific transcriptome in high-risk NDMM patients. The PCL-like status showed significant prognostic value in outcome assessment, potentially improving the accuracy of current risk models.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Zohreh Jahani, Jamshid Davoodi
Summary: Metformin, an anti-diabetic drug, has a dual effect on breast cancer cell lines by both upregulating and enhancing the degradation of certain proteins during mTORC1 inhibition.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Review
Biochemistry & Molecular Biology
Jianhao Liu, Ruogang Zhao, Xiaowen Jiang, Zhaohuan Li, Bo Zhang
Summary: Bortezomib is a proteasome inhibitor that has been approved for the treatment of multiple myeloma and other hematological cancers. However, its limited specificity, poor permeability, and low bioavailability hinder its applications. Recent research has focused on the development of BTZ-based drug delivery systems.
Article
Oncology
Tian-Yi Jiang, Xiao-Fan Feng, Zheng Fang, Xiao-Wen Cui, Yun-Kai Lin, Yu-Fei Pan, Chun Yang, Zhi-Wen Ding, Yong-Jie Zhang, Ye-Xiong Tan, Hong-Yang Wang, Li-Wei Dong
Summary: This study identified frequent alterations of PTEN in GBC, showing correlation with poor prognosis, and indicated proteasome inhibitor bortezomib as a promising therapeutic agent. Knockdown of PTEN increased bortezomib efficacy, and further evaluation using PDXs supported the utilization of bortezomib in PTEN-deficient GBC. Mechanistically, PTEN inhibited proteasome activity and bortezomib sensitivity through ARE-dependent transcriptional regulation, with involvement of the BACH1 transcriptional suppressor.
Article
Oncology
Gregoire Quinet, Wendy Xolalpa, Diana Reyes-Garau, Nuria Profitos-Peleja, Mikel Azkargorta, Laurie Ceccato, Maria Gonzalez-Santamarta, Maria Marsal, Jordi Andilla, Fabienne Aillet, Francesc Bosch, Felix Elortza, Pablo Loza-Alvarez, Brigitte Sola, Olivier Coux, Rune Matthiesen, Gael Roue, Manuel S. Rodriguez
Summary: The research identified an enrichment of autophagy-lysosome system (ALS) components in bortezomib (BTZ)-resistant cells in mantle cell lymphoma (MCL) patients. By blocking proteaphagy, the normal proteasomal activity was reactivated and the BTZ antitumor effect was restored in vitro and in vivo models of BTZ resistance. These findings suggest a proteolytic switch from the ubiquitin-proteasome system (UPS) to ALS in B-cell lymphoma refractory to proteasome inhibition, opening up new therapeutic avenues for treatment-resistant tumors.
Article
Biochemistry & Molecular Biology
Kyota Ishii, Mayuko Hido, Misaki Sakamura, Nantiga Virgona, Tomohiro Yano
Summary: This study demonstrated that T3, TOS, and T3E enhance the sensitivity of the proteasome inhibitor BTZ in solid cancers by modulating the activity of NFE2L1. Inactivation of NFE2L1 by T3, TOS, and T3E is essential to potentiate the cytotoxic effect of BTZ in solid cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)